Comparative Pharmacology
Head-to-head clinical analysis: KENALOG 80 versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG 80 versus OTICAIR.
KENALOG-80 vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-proliferative effects. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, which reduces prostaglandin and leukotriene synthesis. It also suppresses cytokine production and immune cell migration.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
60 mg (1.5 mL) intramuscularly (deep IM) as a single dose for allergic/ inflammatory conditions; intra-articular or soft tissue injection: 10-40 mg for large joints, 5-25 mg for medium joints, 2.5-10 mg for small joints; intralesional: up to 1 mg per injection site, repeated as needed.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours for triamcinolone acetonide; prolonged in hepatic impairment (up to 6–8 hours).
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine, with minor biliary/fecal elimination (<2%).
Renal: 85% unchanged; biliary/fecal: 10%
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid